- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02310984
PICTURE Breast XS: Patient Information Combined for Local Therapy oUtcome Assessment in bREast Cancer - Cross-sectional (PICTURE XS)
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Breast cancer is the most common cancer to affect women in Europe, having a lifetime risk of 1 in 9. It is an increasingly treatable disease, and 10-year survival now exceeds 80%. The primary treatment for breast cancer is surgery, which may be used in conjunction with adjuvant therapies, such as chemotherapy and radiotherapy. Given the high breast cancer survival rate, many women will live for many years with the potentially disfiguring aesthetic consequences of their surgical and therapeutic treatment. A good aesthetic outcome is an important endpoint for breast cancer treatment and is closely related to psychosocial recovery and quality of life.
When a woman faces a breast cancer diagnosis, and surgery is proposed, several options are available. The decision as to which type of surgery to offer patients is largely subjective and based almost exclusively on the judgment and experience of the clinician. The cosmetic outcome of surgery is a function of many factors including tumour size and location, the volume of the breast, its density, and the dose and distribution of radiotherapy. In breast-conserving surgery, there is evidence that approximately 30% of women receive a suboptimal or poor aesthetic outcome; however there is currently no standardised method of identifying these women.
The PICTURE project aims to address these issues by providing objective tools, tailored to the individual patient, to predict the aesthetic outcome of local treatment. Using a combination of 3D photography and routinely acquired radiological images (i.e. mammography, ultrasound and MRI, when available), together with information about the tumour (size, location, shape etc.) we will develop techniques to biomechanically model the anatomy of the breast and the effect of surgical removal of cancerous tissue. This digital patient representation and associated predictive tools will enable alternative surgical strategies to be explored and the consequences of the available options, with respect to the appearance of the breast, to be visualised. This will aid communication with the patient of the type of breast surgery recommended by the surgeon, and will empower patients to take an active role in a shared decision making process.
The study will develop tools to enable the patient's aesthetic appearance after treatment to be objectively evaluated. Current techniques use subjective methods, such as assessment by an expert panel, or computer analysis of 2-dimensional photography to estimate, for instance, breast asymmetry. By adopting recent developments in low cost 3D photography and depth sensing technology, we will develop a standardised, reproducible analysis tool which will base the aesthetic outcome evaluation on both the 3-dimensional shape of the reconstructed breast and its volume. This will establish standardised quality assurance and evaluation procedures, enabling institutions across Europe to be compared and factors that have a positive or negative impact on surgical outcome identified.
In summary, the demonstrator created by the PICTURE project will integrate models of surgical techniques and treatment schemes, clinical patient data, multi-modal imaging and individualised models of patient anatomy to build a personalised, digital representation of the patient. The aim is for this to be used as an aid to surgical planning, via simulation of the cosmetic effects of breast conserving surgery, as a decision support tool to communicate the available options to the patient and to enable standardised evaluation and a safe outcome of the procedure. The demonstrator aims to empower patients and will have a direct impact on their care and quality of life.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Lisbon, Le Portugal
- Champalimaud Cancer Center
-
-
-
-
-
Leiden, Pays-Bas
- Leiden University Medical Center (LUMC)
-
-
-
-
-
London, Royaume-Uni, NW3 2QG
- Royal Free Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Women who have undergone breast conserving surgery for early breast cancer more than one year ago.
- Written informed consent obtained.
Exclusion Criteria:
- Unable to provide written informed consent.
- Younger than 18 years.
- Benign breast disease.
- Women who have had a mastectomy.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Evaluate the factors that determine aesthetic outcome after treatment for early breast cancer
Délai: Single assessment on one day, beyond one year from date of primary surgery.
|
The primary aim of this study is to evaluate the factors that determine aesthetic outcome after treatment for early breast cancer, based on a consensual classification obtained with a consensus panel.
The information thus obtained will be integrated into the demonstrator (a personalised digital representation of the patient).
|
Single assessment on one day, beyond one year from date of primary surgery.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Comparison of the characteristics of this patient group with the group used to make the demonstrator in PICTURE L (composite outcome).
Délai: Single assessment on one day, beyond one year from date of primary surgery.
|
Comparison of the characteristics of the primary tumour in this patient group with the group used to make the demonstrator.
The characteristics include: primary tumour side, quadrant, size, and hormone receptor status.
|
Single assessment on one day, beyond one year from date of primary surgery.
|
|
Comparison of the characteristics of this patient group with the group used to make the demonstrator in PICTURE L (composite outcome).
Délai: Single assessment on one day, beyond one year from date of primary surgery.
|
Comparison of the characteristics of treatment received in this patient group with the group used to make the demonstrator.
The characteristics include: details of surgery, chemotherapy, radiotherapy and adjuvant hormonal therapy.
|
Single assessment on one day, beyond one year from date of primary surgery.
|
|
Comparison of the characteristics of this patient group with the group used to make the demonstrator in PICTURE L (composite outcome).
Délai: Single assessment on one day, beyond one year from date of primary surgery.
|
Comparison of the characteristics assessed by questionnaire of this patient group with the group used to make the demonstrator.
The characteristics include: measures assessed by the questionnaires (EQ-5D-5L, QLQ-C30 & BR23, and BREAST-Q).
|
Single assessment on one day, beyond one year from date of primary surgery.
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Mo Keshtgar, MB BS, FRCS, Royal Free Hospital NHS Foundation Trust
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- UCL 13/0354
- 14/LO/0428 (Autre identifiant: HRA NRES Committee)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .